

Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use (II)

- 5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonneuve et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

20

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

30

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1  
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during  
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeitsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce  
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also  
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and  
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonneuve et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was  
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurstonen et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonneuve et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led
- 5 to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191,

5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl.

Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999;

Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-

2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by

escalation of therapeutic doses a plateau level of therapeutic efficacy was

achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60,

2178-2189, 2000). Similar results were observed upon interference with the

Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999;

Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al.,

Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon

25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby

30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

- 5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of  
10 Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.  
15 Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- 20 (a) compounds which inhibit receptor tyrosine kinase activity,  
(b) compounds which inhibit ligand binding to receptors,  
(c) compounds which inhibit activation of intracellular signal pathways of the  
receptors,  
(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,  
(e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents  
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,  
(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


- 30 A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

- kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. Assoc. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: 5 ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Assoc. Cancer Res., San Franzisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as Pseudomonas exotoxin 10 15 A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593-4599. Ligand-binding receptor domaines are described by Kendall & Thomas 20 (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579. Receptor blocking antibodies have been described by Imclone ( $\alpha$ -p1C11, US 25 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides habe been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.
- 30 Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

15



20

1

in which

**r** has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

$R_3$  und  $R_4$

a) each independently from each other have the meaning of lower alkyl.

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

G

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or

20

$C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T

independently from each other have the meaning of N or CH ,

25

with the provisio that not more than three of these

Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
 R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or  
 lower alkyl,  
 X has the meaning of imino, oxa or thia;  
 5 Y has the meaning of hydrogene, unsubstituted or substituted  
 aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and  
 Z has the meaning of amino, mono- or disubstituted amino,  
 halogen, alkyl, substituted alkyl, hydroxy, etherified or  
 esterified hydroxy, nitro, cyano, carboxy, esterified  
 carboxy, alkanoyl, carbamoyl, N-mono- or N, N-disubstituted  
 carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,  
 phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,  
 phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,  
 phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if  
 more than one rest Z is present ( $m \geq 2$ ), the substituents Z are  
 equal or different from each other, and wherein the bonds  
 marked with an arrow are single or double bonds; or an N-  
 oxide of said compound, wherein one or more N-atoms carry  
 an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranyl acid derivatives of general formula IV

30



in which

A

has the meaning of group  $=NR^2$ ,

W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,


Z

has the meaning of the group  $=NR^{10}$  or  $=N-, -N(R^{10})-(CH_2)_q-$ , branched or unbranched C<sub>1-6</sub>-Alkyl or is the group

5


10

15




or A, Z and R<sup>1</sup> together form the group

20



	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
5	R <sub>a</sub> , R <sub>b</sub> , R <sub>c</sub> , R <sub>d</sub> , R <sub>e</sub> , R <sub>f</sub>	independently from each other have the meaning of hydrogen, C <sub>1-4</sub> alkyl or the group =NR <sup>10</sup> , and/or R <sub>a</sub> and/or R <sub>b</sub> together with R <sub>c</sub> and/or R <sub>d</sub> or R <sub>c</sub> together with R <sub>e</sub> and/or R <sub>f</sub> form a bound, or up to two of the groups R <sub>a</sub> -R <sub>f</sub> form a bridge with each up to 3 C-atoms with R <sup>1</sup> or R <sup>2</sup> ,
10	X	has the meaning of group =NR <sup>9</sup> or =N-,
	Y	has the meaning of group -(CH <sub>2</sub> ) <sub>p</sub> ,
	p	has the meaning of integer 1-4,
	R <sup>1</sup>	has the meaning of unsubstituted or optionally substituted with one or more of halogen, C <sub>1-6</sub> -alkyl, or C <sub>1-6</sub> -alkyl or C <sub>1-6</sub> -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
15	R <sup>2</sup>	has the meaning of hydrogen or C <sub>1-6</sub> -alkyl, or form a bridge with up to 3 ring atoms with R <sub>a</sub> -R <sub>f</sub> together with Z or R <sub>1</sub> ,
20	R <sup>3</sup>	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C <sub>1-6</sub> -alkyl, C <sub>1-6</sub> -alkoxy or hydroxy,
25	R <sup>4</sup> , R <sup>5</sup> , R <sup>6</sup> and R <sup>7</sup>	independently from each other have the meaning of hydrogen, halogen or C <sub>1-6</sub> -alkoxy, C <sub>1-6</sub> -alkyl or


$C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or  $R^5$  and  $R^6$  together form the group



- 5       $R^8$ ,  $R^9$  and  $R^{10}$  independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts.

These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V






- 15      V,

in which





$R^1$  has the meaning of group

- 20






in which R<sup>5</sup> is chloro, bromo or the group -OCH<sub>3</sub>,



in which R<sup>7</sup> is -CH<sub>3</sub> or chloro,

100% 200% 300% 400%




in which R<sup>8</sup> is -CH<sub>3</sub>, fluoro,  
chloro or -CF<sub>3</sub>

in which R<sup>4</sup> is fluoro,  
chloro, bromo, -CF<sub>3</sub>,  
-N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or  
-CH<sub>2</sub>OH

in which R<sup>5</sup> is  
-CH<sub>3</sub> or chloro

5 R<sup>2</sup>

has the meaning of pyridyl or the group



and

10 R<sup>3</sup>

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under 15 compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of 25 main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims 30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-

10 pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinatesTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the provisio that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical

20 compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as

25 mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerose, thrombic microangiopathic syndrome,

30 transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore, a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

25 For oral application especially suitable are tablets, pills or capsules with talcum and/or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with

- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in  
sequential order such that the biological response to interference with one  
ligand/receptor system overlaps with the biological response to interference with a  
second ligand/receptor system. Alternatively, combined functional interference  
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and  
targeting of cytotoxic agents via VEGF/VEGF receptor systems or via  
Angiopoietin/Tie receptor systems can be performed simultaneously, or in  
sequential order such that the biological response to functional interference with a  
ligand/receptor system overlaps in time with targeting of cytotoxic agents.

10 15 The invention is also directed to a substance which functional interferes with both  
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which  
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor  
systems.

- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,  
VEGF-D, PIGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2  
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).  
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and  
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor  
25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal  
purposes. Such diseases are, for example, cancer, cancer metastasis,  
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of  
30 the present invention can be applied orally, parenterally, or via gene therapeutic  
methods.

Therefor the present invention also concerns the use of pharmaceutical  
compositions for the production of a medicament for the treatment of tumors,

- cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections
- 5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

10  
9  
8  
7  
6  
5  
4  
3  
2  
1

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5   **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10   Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector

15   (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the

VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,

20   2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days.
- 10 This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.
- 15

**Example 2**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in

- 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with

- Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of 5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional 10 interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

5 10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100

**Example 3**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10  
11  
12  
13  
14  
15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

10  
11  
12  
13  
14  
15

**Example 4**

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is

- 5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

20

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the  
 10 coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex  
 15 (compound I + compound II, treatment group 4) resulted in an inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days.

- The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the  
 20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

**Example 5**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to

- 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

15

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

10

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

**Example 6**

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to

- 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with

daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19

scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of

15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

- Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducting L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in an inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

### Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the

5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock+VEGF-A	=	treatment group 2
sTIE2-cl13	=	treatment group 3
sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25 Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in 5 Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

### Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

<140>

- 13 -

1310

1835

<211> 1993  
<212> RNA

<213> Human

<400> 1

60 <210> 2  
<211> 581  
<212> DNA  
<213> Human

&lt;400&gt; 2

5 gttcttagatt gtttttattca gtaattagct cttaaagacc ctggggccctg tgatcacccag 60  
 acactaaacaa cagtctctat ccagttgtcgt gttctgggtc acgtgatctc cccatcatgta 120  
 tcacaattact tcctgtggcc cattaggaa gtgtgtaccc cgggagctat ttgcctgttg 180  
 agtgcacaca cctggaaaata tactgtctc ccacatcagt gagaataatgg 240  
 tggccggtta gcaagatata actatgcaat catgcaacaa agtcgcctaa taacatttca 300  
 ttatattacag gactaaatgt tcattatgtt ttgtaaaggta tgaaatccata acctctgcag 360  
 10 agttatagt catacacagt tgatccccat ttataaaaggc aagaaatgtt tgttttctc 420  
 aaatgtcga ctggactgaa aaactcccg tttcccaatc actggagtgt tgccgtatgta 480  
 aagaaaaatct ttagcaatttta gatgggagag aaggaaata tgacttgaaa tgtaggcct 540  
 caccccccata tgacatccctc catgacccctc ctgtatgt 9

15 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

&lt;400&gt; 3

tagagatgtt gggtgtatgac ccccggtatc tggagcagat gaatgaagag tctctggaa 60  
 tcaccccaatc tgatgtccat tacatcacag aggacatgtt catgtcgccg aacctgtatgg 120  
 20 gacactctgg gttgtatgtt aaaaatgtt ggtcttccac ctgcagctct tcgaaacac 180  
 ttgttaatgt tcgtggccatc agtactgtt ctcttccaca gactatatgtt cgaaaaacca 240  
 agacccctccat tgatggacatc aggttggatc tgatgtatccatc cagatccatc cagaaagact 300  
 tcttcggcat tgcaggcttg tgcaggaca ctgcgtccatc ttacacccctt ggtatggcc 360  
 atgaactgtt tgaggaatgc ctcttattgtca acagttgtt ggcccaatc tgcatcaaca 420  
 tccaatgttccatc aaaaatgtt ccataacttctt ttcactgtt ccactatgtt 480  
 30 atgaagtttccatc agagttgtt gtgttaatgtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 <213> Human

&lt;400&gt; 4

40 cccacaaacac agggccctgt aaacacgcca gcctctccctc tgggttcagc ttggcccaatgtt 60  
 cctgtctact ggatcacac ccattgttgcg tggggatcg tggggatcgccatgg ccgcctgtgc 120  
 ccacggggag tgatggaaatg accttgcgttccg tgatgggttccg tgatgggttccg 180  
 ggggtgggttccg tttggcccttc cttcccccgtt gaggccatgtt cttcccccgtt 240  
 45 gcaacaaactc cagccgttca gagccagggyt agatgtatccatc aaccacaaatc atgaatgtt 300  
 tgaatgtt ccatttcgtt gggcgagaga caaaggatgtt caccaggatgtt caccaggatgtt 360  
 ctgcgttgcg cacaacaaatc gggtccatgtt ccacccgttca caggccatgtt ccgcctataga 420  
 ggaaggccctgc ctcttgcaca ctcttgcaca gacactgttgc gacatgttgc gacatgttgc 480  
 ctccggatgtt ccgcgttgc accttgcgttccg ctttggcccg ctttggccatgtt ccgcctataga 540  
 cggccgcacatc cccgcgttgc accttgcgttccg ctttggcccg ctttggccatgtt ccgcctataga 600  
 50 ctttgcgttgc cggccgttgc accttgcgttccg acaggatgtt gacatgttgc gacatgttgc 660  
 ggggtgggttccg tttggccatgtt ccgcgttgc acaggatgtt gacatgttgc gacatgttgc 720  
 aggccgttgc ataggatgtt ccgcgttgc accttgcgttccg ctttggcccg ctttggccatgtt ccgcctataga 780  
 actgtgttgc accccacatc gactccgttgc acaggatgtt gacatgttgc gacatgttgc 840  
 agagacccgttccg cggccgttgc acaggatgtt gacatgttgc gacatgttgc 900  
 55 actttccatc gaaatgttgc acaggatgtt gacatgttgc gacatgttgc gacatgttgc 960  
 gcacgttgc acaggatgtt gacatgttgc gacatgttgc gacatgttgc gacatgttgc 1020  
 gtgttgcacatc cccgttgcacatc cccgttgcacatc cccgttgcacatc cccgttgcacatc 1080  
 gggccggatgtt ccgcgttgcacatc cccgttgcacatc cccgttgcacatc cccgttgcacatc

<210> 5  
 <211> 1015  
 <212> DNA  
 <213> Human

&lt;400&gt; 5

gaggataggg agcctgggtt caggagttgtt ggagacacag cgagactctg tctccaaaaa 60

<210> 6  
<211> 2313  
<212> DNA  
<213> Human

<400> 6

65 <210> 7  
<211> 389

<212> DNA  
 <213> Human

&lt;400&gt; 7

5       <210> 6  
 gccactggat tcatgttag aaaaatagg ataaatctg taaaagaaatg aagacccgtc 120  
 tattctaaaa tcagatccctt acagatccag atttcaggaa acaaatacat aggggactaa 180  
 10      cttcccttgt tcagatgtttt ttttctccct tgccccccgc tatataatat gaggaaatgt 240  
 tgactttttt aaagtgtttt agttttccat ttctttgata tgaaaaatggaaatgttccggaa 300  
 gaaccctggag ctatataaa tctatgtggc tagtgcgtat atatggtctt gaattttgttc 360  
 tccttttgtg gtgtcccgat ggttaacatc

15     <210> 8  
 <211> 157  
 <212> DNA  
 <213> Human

&lt;400&gt; 8

20     <210> 60  
 tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt gggttttag 60  
 gaagcaggaa gcaagccac tcaaaatgtt aatttgcat gaggatcca gtaactttct 120  
 cctcaatctg tgaactatata tggatgttga tatttttg

25     <210> 9  
 <211> 561  
 <212> DNA  
 <213> Human

&lt;400&gt; 9

30     <210> 60  
 aatagtcaaa acataaaacaa aagctaatta actggcaactg ttgtcacctg agactaagt 60  
 gatgttgttgg gctgacatc aggttcagcc agcagagaaa gaattctgaa ttccccttgc 120  
 35     tgaactgaa tattttgtt acaatgttgc acaaatctgt tggttatttc ttttctactt 180  
 accatattta aattttatggat tataaaccggc ggacatagtc aaccccttgc tgatgacat 240  
 ttctgttattt ttgtcgttgc aatctctgttgc gacgttact tggttgcattt caagatttt 300  
 tggatgttgg aggaaaaatgt aatgtacccctt tttttttttt gatgtatgc 360  
 tcaccaatc aaaaatgttca attttgttgc aatgtttaatg atatccatca ttgttattaa 420  
 tttaaacatc aatgttgcattt cttatgttgc aattttttatggatggatca tccctgtatc 480  
 40     ttttttttttt aattttctctg cacacacagg acttcttcatt ttccaaataaa tgggtgtact 540  
 ctggcccaat ttcttagaaaa a

45     <210> 10  
 <211> 1508  
 <212> DNA  
 <213> Human

&lt;400&gt; 10

50     <210> 60  
 cacaaacacg agagacttca cgggtctggct gaggcacccgc agcccttcgt gtcggccac 60  
 tcgcagggtc attcttctgc acgagccctt ctgtcccgat ccataagcac ggtcagtc 120  
 ggggtcggcga gcagttacggc gacaaggatcc acggcagatc cttctgttgc aagactgtca 180  
 ggatcatctt ttcctcccggtt gctgtgttgc gatggcataa tccgggtgc acccaaatct 240  
 gaggtcaacgc caagggtgttgc taaggccactg acaaggaaatggatggccctt gcaacgcctad 300  
 55     agggtgttgc gactgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 360  
 tcagactgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 420  
 actttgtgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 480  
 ttgtgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 540  
 ggtgtgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 600  
 60     aaatgtgttgc aagggtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 660  
 aacacgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 720  
 catatcaatgtt aagggtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 780  
 atgtgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 840  
 65     gctgtgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 900  
 ctgcgttgc ttgtgttgc ttgtcaatgtt aagggtgtca ctatcccaatg ggcctctgc 960  
 ctaaaacacgc acagacacttc ctggcaaaatggatgttgc ttgtcaatgtt aagggtgtca 1020

10 <210> 11  
<211> 389  
<212> DNA

<210> 12  
<211> 981  
<212> DNA  
<213> Human

<210> 13  
<211> 401  
<212> DNA  
<213> Human

65 <210> 14

<211> 1002  
<212> DNA  
<213> Human

5 <400> 14

<210> 15  
<211> 280  
<212> DNA  
<213> Human

30	<400> 15 cgagggtggc ataatattcc aaacattt aactgttt caatcttaac
35	
40	<210> 16 <211> 2041 <212> DNA <213> Human

<400> 16



agcaatcaag ccacaggct tatttcataat gtttcccaa ctgtacaatg aactattctc. 2040  
 atggaaaaatg gctaaagaaas ttatattttg ttctatgtc agggtaaaaat aaatacattt 2100  
 tggtccaaatc gaaaataat tttatccatggaaat gttttttctt acactttgtc atgttaatgtt 2160  
 aaaagctttt ggttgcacat ttatggaaat gttttttctt acactttgtc atgttaatgtt 2220  
 5 ctactcatt tteactttttt tccactgtat acagtgttct gttttgacaa agttatgtttt 2280  
 tattacttac attttaaatttt ttatggca aaagaacgtg ttttatgggg agaaacaaac 2340  
 tctttgaagc cagttagtgc atgccttgca caaaatgtat gaaatctaga aaagatttgt 2400  
 tgcaccctt gttttatctt gaaacagggg caaaagggc actgggcact ttccacaac 2460  
 tttttagtgc aaaaaagggtt ctatattttt tttaaaaaaaa taaaataaaaa cataaatattt 2520  
 10 actttccat attccttcg ctatattta gtaatattt tattttatg taaaagttcta 2580  
 atgaaatgtt aatttgcata gcaaaattct gctttttt catcccttg tgtaaacatgt 2640  
 ttaataatgtt gccccatcaat aatatccatg gtaaaggatgta acacgggtt acagttaaaata 2700  
 aatgtgaat ttttcaatgg taaaaaaaaaa

15 <210> 19  
 <211> 276  
 <212> DNA  
 <213> Human

20 <400> 19  
 ctcccttaat gatTTaaaaa taaattggat aaacatatgata tataaaatgg gtacttttaga 60  
 aaccgcctttt gcatattttt tatgtacaaa ttctttgtata caattcccgat gttcccttata 120  
 25 tattccctat atagcaaaaccc aaaaccaggat cctcccaactt gcatgtctca agtccctgtg 180  
 gagcacttgc gcaacttgc ggccttactt gtttttgcacaaaatgtgc gaaaggaggat 240  
 gggaccattt aaataccatcg gccgcgacca cgctgg  
 <210> 20  
 <211> 2361  
 <212> DNA  
 <213> Human

30 <400> 20  
 attttgcacatc cttttttttt gttttttttt tgaggggccat aagcttattttt 60  
 cccatgtttt tagagggttccatccatggat tttttttttt ccggaaagggtt tttttttttt 120  
 35 cagatgtttt cagcagggttccatccatggat ccggaaaggat tttttttttt gttttttttt 180  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 240  
 atgtggggctt cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 300  
 acacacatggat cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360  
 40 ttggcaaaaggat ccacatggat cttttttttt tttttttttt tttttttttt tttttttttt 420  
 accatcttctt cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480  
 gaaatgtttt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600  
 45 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 840  
 50 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 900  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 960  
 aaggccggat cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1020  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1080  
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1140  
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200  
 55 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1260  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1320  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1380  
 acccccttctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1440  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1500  
 60 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1560  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1620  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1680  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1740  
 65 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1800  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1860  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1920  
 agaaaaacgaga tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt



<210> 24  
<211> 1626  
<212> DNA  
<213> Human

<400> 24

<210> 25  
<211> 1420  
<212> DNA  
<213> Human

<400> 25  
gttcaaggatt gtttctactt ctgaaatctg tatagttacac tggtttgtaa tcattatgtc 60



ggtgaaactca gtgcattggg ccaatgggtc gacacaggct ctggcagccca caaccatctt 60  
 gctgtttctg acgggttggc tgctggggg ctttccccctt actgtcatgg tggggatctt 120  
 tggaaagaad aacggccagcc cctttgtatgc accctgtcgcc accaaagaaca tcgccccggga 180  
 5 gattccaccc cagccccgtt acaagtctac tgcacatccat atgactgtt gagggttctt 240  
 gcctttcaatgttgcatccatctt gcccacgttat ggggtcggtt 300  
 gcagttactt ttgtacggca ttcctttctt tgccttcggcc atccctgttgc tggtgggggc 360  
 ttgcatttcc attgcacttca cttacttccat ttgttgcggg gaggattacc gctgtgtgtt 420  
 ggcgtatgtt ctggatgttgc gtcaccccgcc cttttttccatc ttcccttactt cagtttttca 480  
 10 ttatgcgggg cgctccaaca tgcgtgggg agtacagaca ttagagtttctt tccgtactt 540  
 ctatcaactt ctggatgttgc ttccttcctat gtcggccacc attcctttttt tttttttccat 600  
 aaagtccatc cggatatactt atgtttaacctt caaatgttgc tgatgttgc tttttttttttt 660  
 tattgtgtt ctcccttccat cttcatggcc ttgttgcactt ttccttccatc ttctttcttgc 720  
 15 attgcacttgc ttgttgcgttgc gtcaccccgcc cttttttccatc ttcccttgc 780  
 ccagagagggg cttggaaattt aaaaatcttccatc ttacataaag gattatataat ttgttgc 840  
 taatgttgc ttatgttgc ttcgttgc ttttttttaca attacaaaaa taaaatttat 900  
 taagaaaaaa aaaaaaaaaa aaaaaaaaaa

<210> 29

<211> 1775

<212> DNA

<213> Human

<400> 29

25 gaacgtgtat ggaaattttg gaggatgtct gagaaaaatgt cggaaaggat tttggccaa 60  
 accagaaaaac gccaatgtcc taggaattcc ctccaaaaat gtttcccaa aaattactca 120  
 ttgacatccat aaatgttgcact ttggctgggg cagccggggc ggccttccat cctgtgtgggg 180  
 30 cgccggcggtt gcttttctt ctgttgcacttccat cccaaactcg ttactctgc gtttatccat 240  
 aggataaaacg caccgtgtt acaggatgac cagaacaccc acgtcgatcc ggaaggccggc 300  
 cagccgggtt gacgtggggca ttgttgcgtt acggcaaaatg acgttcatca tgaagggtt 360  
 gaaacgttgc taggttgcaggg cttccgggg ctagatgttgc actgtacttca acttgcgtt 420  
 caaaacaggatc tggggcggca tgaaggaggg accaaaaggatc tagaccccggt tgacgaaatgt 480  
 35 gtttgcatttac cagggatacc acgttttata ttgttgcatttccatc agggatgttgc tttttttttt 540  
 cccgacacaaatg aggggttacatc tgccgttgcacttccatc ttgttgcatttccatc agacagccat 600  
 ctgcgttttc ctcttcatttgc ctgttgcatttccatc gtttttttttccatc tttttttttttt 660  
 ccaaaaaataatgttgcatttccatc atgccttccatc cttttttccatc acgttcatca ggccttccatc 720  
 accccggccgg accaggacccca gtcgttgcacttccatc ttgttgcatttccatc acggacaaatgt 780  
 ctcgtgttgc acggacggcc acggacttgc ttgttgcatttccatc ttgttgcatttccatc 840  
 40 ctctttccatc aaatgttgcatttccatc ttgttgcatttccatc gtttttttttccatc tttttttttt 900  
 tgcgacaaatgttgcatttccatc ttgttgcatttccatc gtttttttttccatc ttttttttttccatc 960  
 ctcatcgcacatcccttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1020  
 gtggatccatc acggcgcggcc gccccccgttgc gacccatgttgc ttgttgcatttccatc ttttttttttccatc 1080  
 45 ctccgtgttgc gacccatgttgc ttgttgcatttccatc ttttttttttccatc ttttttttttccatc 1140  
 gaacaggatgttgc gacccatgttgc ttgttgcatttccatc ttttttttttccatc ttttttttttccatc 1200  
 cacatcgccatc ggccgggggg accggccatcaaaatgttgc ttgttgcatttccatc ttttttttttccatc 1260  
 cagccggcggtt cggccatgttgc acacttgcgttgc ttgttgcatttccatc ttttttttttccatc 1320  
 50 cccatgttgc ttgttgcatttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1380  
 catgttgcgttgc gtcacccatgttgc ttgttgcatttccatc ttttttttttccatc ttttttttttccatc 1440  
 ttttttttttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1500  
 tacagaaaaatgttgcatttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1560  
 gaccagggttgc atgttgcatttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1620  
 ctgcgttgc gccccccggcc cggatgttgc ttgttgcatttccatc ttttttttttccatc ttttttttttccatc 1680  
 55 gcccccacccatgttgc acatgttgcatttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1740  
 gcccccacccatgttgc acatgttgcatttccatc ttttttttttccatc ttttttttttccatc ttttttttttccatc 1800

<210> 30

<211> 1546

<212> DNA

<213> Human

<400> 30

65 aaaataagta ggaatggca gtgggttatttccatc acatttacta caccttttccatc atttgttataat 60

aaggcccttcg cagggtggca gggaaattgttgc cctgcctgttcttgc ttttttttttccatc ttttttttttccatc 120

acacatcta cgggcacat ggaactgtt caagtgacca ttctttttc tctgcccagt 180  
 atttcgcaga gtaacagac aggttgtt gaggccgact ataatttcg tttgtttgtt 240  
 acaaaaaaa cacttataaa aacaaaaaaa acagaatcat tttttttttt tttttttttt 300  
 ccaaaactg gaacaactt taaggaaaa atccaaatc aattttttttt aattttttttt 360  
 5 atgtcaacat ctactttttt aacaatggaa gatggaggat tttttttttt tttttttttt 420  
 gtcaggaga atgactccat catttcaaac gtaacatggaa caatgtttttt tttttttttt 480  
 gttgttca cattacaaay ttcccaaaaaa aagactgtt tttttttttt tttttttttt 540  
 10 acagaatatac caggtagtgtt tttttttttt tttttttttt tttttttttt tttttttttt 600  
 atcccaatc caggtttcaat tttttttttt tttttttttt tttttttttt tttttttttt 660  
 gttgtttttt aatccaaatc tttttttttt tttttttttt tttttttttt tttttttttt 720  
 gtgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780  
 atgtgtgtt gggccatcc gggccatcc gggccatcc gggccatcc gggccatcc 840  
 aaaaagggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 900  
 gcacaaaggaa aaaaaaaatc tttttttttt tttttttttt tttttttttt tttttttttt 960  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1020  
 aatcccaatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1080  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1140  
 15 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1260  
 20 gggggaaaat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1320  
 atttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1380  
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1440  
 gtatataatac tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1500  
 aatactctaa aataactata acatgactgt gaaaatggca aaaaaa  
 25 <210> 31  
 <211> 750  
 <212> DNA  
 <213> Human  
 30 <400> 31  
 cacttggca ccccccattttt cttttttttt gggaaatctgg aggggcaaaaaa aggtgtgtt 60  
 35 aagggaatg cctctgttgg cccaaaaaaaat tttttttttt ctatgtttagg aatggaaatgg 120  
 atagcaaatg gatctttttt ggcccttccctt ggagoatgoc tttttttttt tttttttttt 180  
 cccactaaatg cagaacatgg cggatgtttt tttttttttt tttttttttt tttttttttt 240  
 aacacgttcc ctccatattttt aaaaatgttgg tttttttttt tttttttttt tttttttttt 300  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360  
 40 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540  
 actggccccc ttgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600  
 45 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660  
 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720  
 ccaaaaggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780  
 <210> 32  
 <211> 1620  
 <212> DNA  
 <213> Human  
 50 <400> 32  
 gcaattttttt cttttttttt aacgactcccc agtaattttt tttttttttt tttttttttt 60  
 55 gtgcgcgtt ctatataac gttttttttt cttttttttt tttttttttt tttttttttt 120  
 ctgggtttttt ttggaaatggaa atgttggaaa aaaaatccatca tttttttttt tttttttttt 180  
 atctgtgttca actctgtgttca tacctgtttttt atgtttttttt tttttttttt tttttttttt 240  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 300  
 60 atgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360  
 aaaaaaaaaat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420  
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540  
 65 gggttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600  
 attttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780





	gagcggtggg	actttgacag	ctgcaccac	tgtactgcc	tgccaggcga	gacccttcg
	tcggcgca	gtgcggcccc	cttgcctgt	gttgaggccc	tcacaggctc	aggaaatgg
5	tgcggatgt	gtccagaat	gtatgtccca	ggaccaaccc	ataatccat	tgagaagaca
	aaccatcgag	gagagggtta	cctggagggt	ccccctgtgc	ccacgcactg	tgaaaatgt
	atgttcatac	tccttagata	atagggttc	tcscaggtag	attacagaga	taaaggctg
	cacccaatgt	aaggatcttc	actggactcc	atgttcctag	ttgtggttcc	cataataata
	tgcgtctta	ttataatagc	atcttcatt	atacaatgc	agaaaaatcg	gataccactg
10	ctttgtgtt	atcgaaaccc	ataaactagg	tcttccttaa	ataatcggt	atgtatctgt
	gactgcaga	aaggaaaccc	agtccgggt	gaacgttccc	agaatgtatc	aagaatggc
	gacccatgt	caaggatcc	tggtttctac	agcatgcata	aacaaaccca	tctacaggca
	gacaatttc	accaaacagt	gtgaaagaag	gcaacttaga	tgagggttc	aaagacggaa
	gacgactaa	tctgtctta	aaagaatgt	aaatgttgc	actgttgc	gtggatgtt
15	ttggatgtt	actgtgtat	cagcgtca	acccttactg	gttgggtct	gtctacagca
	atgtcgaaa	caacgcattcc	cacttttctc	gacaaatata	gaccaatgt	tttttttagaa
	ccaaatgtt	taaaggttgt	aatagatata	tgccctgtaa	atagctgtat	agatattttg
	ggtggggaca	gtgatgtttt	atggggaaag	gggtgggggg	gttgtgttgg	gaagaaaat
	tgtgtcgat	ggctcgggga	gaaacctgtt	aaacataaaag	cagtccgt	gcccggaggt
20	tatttttt	ctatgtgtt	gaaagactgt	ctgtgtgtcc	caaaatgtca	gcctgtatga
	cgacggaaaa	aaaacggcgt	tgccggccag	tcgtccatac	cactttgtaa	cttccacagg
	agoacatcc	accccttttg	cagccatcc	aggcttaaag	caccaatgtt	tttttttata
	cagtcacaa	tcgtatgtt	agtggggaa	cccgaaatgt	ggtttttttt	gtttttttttt
25	aaggcggtt	ttaaggatat	ataatcgatc	acttttttgt	gttttttttt	tcttcbaacg
	caatcaatca	gcccgttct	agcagatgt	gcatgtatc	aaatgtatca	tcattttttgt
	atgtgcac	tggatgtttt	tttttttatac	acgtgcagg	aaatgggggg	agagggtgtt
	gacacccgg	catttttttt	ggcttatata	caactgtttt	tttttttttt	ttttttttttt
30	ttgtgtttt	tttcatatgt	ttttgttgc	tttttttttt	tttttttttt	ttttttttttt
	gactgtttt	ggatgttttt	ttccttttat	atatgtatc	tttttttttt	ttttttttttt
	atttttttt	tatatttttc	aaggcacctt	ttttgttgc	tttttttttt	ttttttttttt
	aaatttttt	aattttatgg	gttattttat	aactatctta	tttttttttt	ttttttttttt
35	ttttgtgtca	tgtgtatata	atatatata	atatcatat	tttttttttt	ttttttttttt
	tgtttttttt	tgtgtatgt	ttttatgaga	tttttttttt	tttttttttt	ttttttttttt
	cattccatc	cagtgtttt	gatcatcttc	aaattttttt	tttttttttt	ttttttttttt
	taactcgat	ttatgtgttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
40	gtgtgtcg	gcgcacggcc	gttttttttt	gttttttttt	tttttttttt	ttttttttttt
	attttttttt	aaaaattttc	cttatttttt	tttttttttt	tttttttttt	ttttttttttt
	ctggccagag	acattttttt	gttttttttt	gttttttttt	tttttttttt	ttttttttttt
	tttttttttt	tcaaaatcc	gttttttttt	gttttttttt	tttttttttt	ttttttttttt
45	aaagggtttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
	tagttatgt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
50	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	ttttttttttt
55	<210> 34a					
	<211> 1036					
	<212> DNA					
	<213> Human					
60	<400> 34a					

```
mylvagdrgl agcghllvsl lgllllpars gtralvcldc deskceprn rpgsivqgvc 60  
gccccttcasqg nescggftgi ygtcdrglrc virpprlngs lteayevags denwtddql 120  
gfkpcnleni agcniingkc ectntcrsn pfefpsqdmc lalkrilee kpdcskrcar 180  
vqfsprcped svliegyapp gecplpsrc vcnpagclrk vcqpqnlhyl vskaskgpe 240
```

ccdlyeckpv fgvdcrtevc ptvqqtacpp dsyetqvrlt adgcclptr cecilsglcg 300  
 pvcevgstpr ivsrgdtpg kccdfvecnw dtkpacvfnm veeygdmlr mdnrcfrcrc 360  
 ggvaicftaq cgeinceruy vpegeccpvc edpvpifng agcyanglil ahgdiwredd 420  
 5 ctfcgvngh rhcavatvcdg tctnpvkvpg eecpvpcfng gctlnccpfgr ltdaqnciee ecrprpkkr 540  
 dincingfkrdh ngrctcqcin tgelcerkq gctlnccpfgr ltdaqnciee ecrprpkkr 540  
 piicdkyckpl glknknhgcd icrckkcpel scskicplgf qddshgclic kcreasasagd 600  
 ppilkskpltd vdgdhkhne swhdgcrcy cngremal gctlpvpcagn pthpgqccp 660  
 10 scaddffvvqk pelstpsch agpggyfveg etwnidsctg ctcchgrvlic etevcppllc 720  
 qnpssrtqdc pcqcdgpfz pselsrrnsvp nyknegdgt flaaqkwpk vctascicids 780  
 viscfseesp svscerpvrlr kgqccpcylk dtipkkvvhc fsgkayadee rwdldscthc 840  
 yclqggqtlcs tvscpplpcv epinvegssc pmcpemvye ptnipiektm hrgevdlevp 900  
 lwptspendi whlprdmhnl qvdydrnsls psedssldsi asvvpviis lsiivqkflf 960  
 ngkkwqipil cwyrtpkpa slnqlvsrd ckgktrvqvds ssgqrmlriae pdarfsqfys 1020  
 mqkqnhlgad nfyqtv  
  
 <210> 35  
 <211> 716  
 <212> DNA  
 20 <213> Human  
  
 <400> 35  
  
 25 gcagtactctg gagttgtctcg cagggggaaa gcgaaacggg ccctgaagt cggggcagtc 60  
 accacggggct cctggggccgct tcggccggc tggggctgag cagcgatctt gctttgtccc 120  
 aagaatggccatcg aggatcatgc cccaaacac acccttcctcc cccggacggc cagatcttc 180  
 30 ggaggcttaga gaaggcatgaa agagtggctt ccacctgtg gcccactgaa aaaagaat 240  
 ccagacttgcgtccatc acataggatggaa acactatgtt tcraaaggag agacggccg 300  
 ttgadggatct ctccgtatcc tccttatatac accttcacactt gaccatacta aacatgttag 360  
 35 aaggtctttt taaggcttta aatgtccaggg tttccatccatc cctgtatgc gacttggata 420  
 gtcagtgttgg agtagacggcgtt ttccatccac cagggttgac ttcaagggtat gatctggtc 480  
 ccatttgtt ctaaagaccc caaacaaaggg tttttccatc tccaggatctt ggacggccct 540  
 tttgtttagt gtctgttaact ctgtgtgtcc cccgttaccc catttgcctca gtgagctcag 600  
 40 ccccatccatc ctaaacagggttggccacagg gattactgag ggttaagacc tttagactgg 660  
 gtttagacc cgtataagacc tcaataaaatg ttgttccctt ccacatcaa aaaaaaa  
  
 <210> 36  
 <211> 395  
 <212> DNA  
 <213> Human  
  
 <400> 36  
  
 45 ccaactacttc atttcttattt ggtggagaaatg attgttagact tctaaggcatt ttccaataataa 60  
 aaaagatgtt atttgatttc caacttttaa acatgtatc tcctttgcctt tttactatcat 120  
 50 tttccatccaaa aaccttggaaa tggaaaggcc cacccttaaa atatctcaga ggctgaaaat 180  
 attgttatttta catttgcattt cttagatcc tttatgtatc ttatgtatctt gcaacttccat 240  
 gccccatggaaa accaaatgtca ggttaccaa tttatgtatcc cttttatgtatc aaacccatata 300  
 tttttatgtatc ttatgtatcc tttttatgtatc ttatgtatcc cttttatgtatc aaacccatata 360  
 55 aagaacggaaa aacggatctt taatttctacc atccct  
  
 <210> 37  
 <211> 134  
 <212> DNA  
 <213> Human  
  
 <400> 37  
  
 60 ccctcgagcg gccggccggc cagggttactttt taccaccgaa ttgttccattt gactttaaaga 60  
 aaccctaaaaa gctgcgttgc tttcagaaac aggcctatca acaccatgtt ggttctccat 120  
 aaggggacacc gtgt  
  
 65 <210> 38  
 <211> 644  
 <212> DNA



<210> 41  
<211> 987  
<212> DNA  
<213> Human

5 <400> 41

aacagacat	ggcacaggac	cttttcattt	caggaaatgt	tgtatgttagg	caggtaacat	60
tgatgccttt	tccaaaaaaa	agagctttcc	tccaaataaa	ggaaatggta	gttatgtgg	120
taaccccccg	ctatccgtcc	ggatgttgc	caccctttaa	gtttgttagat	ggaaagccgg	180
atggatgtgg	aggggaggcc	aaataacacac	cccttcacac	ggctttggat	ggaaaggacg	240
tgttttccac	tcttcgttgc	tcttttttgtt	aaaggccctgg	ggccggatct	ggaaaggacg	300
tgtttttctc	ttttccaaacc	aacagaaaaag	actgtttttcc	aaagggttggag	gttttttttttt	360
aaacacacat	ggccggggcc	caggccacagg	gttggggggcc	tggaaaaagg	ggggccacaaa	420
ggggggggga	ggggctgtta	ggggatgtct	ggttttttttcc	aaaggcttccg	aaacaaggagg	480
gcacaaatgg	caggggccct	tccggcccaat	ggcccatttttt	ggacatggcc	ggggccggaa	540
tgcataatgc	caggcttcaa	aaaaacatgg	tgttttttgcgt	acaggccatgt	tggccgggttt	600
gaacaagcac	aggcttggaa	atccaaatgg	ctgaatccaga	accccttggcc	tgcattatctgt	660
caggccgggt	acccgggttt	attttgcctt	ctaaaaggcc	gtttttttcc	atccgttttttt	720
tgaggcttgt	gataatcttt	tttgggggtt	gttttttttttt	ttaaagataaa	gggtatccaa	780
aatatgttcc	ggccataccat	cccttggaaatgt	gttttttttttt	gtttttttttcc	gttttttttttt	840
cttgggttagt	acctggatgg	ggagatgtttt	aaaaacatccat	gtttttttttcc	gttttttttttt	900
acttgcgttt	aacatgtttcc	tttttttttttt	tttttttttttt	tttttttttttt	tttttttttttt	960
ttttttttttcc	tttttttttttt	tttttttttttt	tttttttttttt	tttttttttttt	tttttttttttt	

<210> 42  
<211> 956  
<212> DNA  
<213> Human

<400> 42

```

ggacgggtgg ggcggacgcg tgggtcgagg agcagggccg ctggcgaactg ccccaaa 60
ggaaggagcc cctgagtccg ctgcggcctc catccccatcg tcggccggaga gcccggatcc 120
tttcggctgtt aaaggcttaa ctaaagactcc ggccccgggc tgcccttgcg gagaccatcc 180
tcaggggatg ttatccgtgt gctcgggaaag ggaggggaaag ggccggggga gggggcacgg 240
caggcgctgtg gcagccccac ccaggcgccgc aggccggccca ggccggggaa gaggatcgac 300
caccgcacccg caccgcactg ctccccccga atccatgttg aaaaaaaatgc taataactgac 360
tcgcagcccc cgccgcctcc ctccgcctcc catccccatcg tcggccggaga gcccggatcc 420
gcggcccttc tcggcccccc agtgcgtcg tggccggatcc caccatcgatcc cccaggatcc 480
gaggatcgty gaaaaccaatg caggccggat gggccggaaacaa aaggccggatcc tgccggcttg 540
ggggaaacggc tgctccggac atccgttgtt tttttccaca tccatcgatcc cccaggatcc 600
gaaggaaaggc catatgtaaa tgatgttgc ttatccaggg tttatccatcg tttatccatcg 660
tgatattaattt catatgtttt acgcggaa gggatccaccc gggatccatcg tttatccatcg 720
ttgtatccatcg tttatccatcg caaggccggc gtgcggccggc aaggccggatcc tgccggcttg 780
tcgcaggace aaggggccggc gggactcggtt ccgcggccggc tttatccatcg tttatccatcg 840
ccttccttgcg gcagaatgtaa ttccgtatcg attcgttgc gggatccatcg tttatccatcg 900
gtatccatcg cttatccatcg cttatccatcg atttaaaaacg qaatatatac cccaaa

```

50 <210> 43  
<211> 536  
<212> DNA  
<213> Human

55 <400> 43

<210> 44  
<211> 1630  
<212> DNA  
<213> Human

5

<400> 44

<210> 45  
<211> 169  
<212> DNA  
<213> Human

**<400>** 45

- 1 -

45 tcttttgtt tttagttttt attttgtat taacaggagt cttattacac atagggtctga 60  
taaaactgtt ttatgatctt cagtcgtt cagtcgtt cagaataatcgat aacgttatgaa 120  
ggaaaaacgca cgcacaa aaaaatgtt gtttggaa cttatgtt -

<210> 46  
<211> 769

50 <212> DNA  
<213> Human

<400> 46

55 tgaggctat atttacata ggcataaata ggaagccaaag cagtattaaat cagcgggtgtaa  
     atttgtcg ttcactttt ataaagtgt acataatccat tcatattttcc aaattttaaaaa  
     acataacttc agttttttacc aacaatgttcc catgggtatcc acgaaggttttcttggaaaa  
     aaacaaaaaaaat aaaaacaaatcc aacaatgttcc ttttttttttccatccatca atagatata  
     aaggttgtatc aggcacatttcc aacatgttcc caatttttttttccatccatca tataataaa  
     ccaaaggacatc ttatggatcc aatggatccatc ttatggatccatc ataaatgtatccatca  
     cttcatataatcc tggacaccaat gccttttttttccatccatca ttttttttttccatccatca  
     ggccagttcc tttttttttccatccatca ttttttttttccatccatca ttttttttttccatccatca  
     catggccatgtt aatggatccatccatca aacatgttcc atatataatccatccatca  
     tatttttttttccatccatca ttttttttttccatccatca aacatgttcc aacatgttcc  
     tttggatccatccatca ttttttttttccatccatca aacatgttcc aacatgttcc  
     ctggcctttttccatccatca aatggatccatccatca aacatgttcc aacatgttcc  
     tttttttttccatccatca aatggatccatccatca aacatgttcc aacatgttcc

ggacatgttgc acggagagga aaggtaggaa agggttaggaa atagaagcc  
 <210> 47  
 <211> 2529  
 <212> DNA  
 <213> Human

<400> 47

5 ttttgtcat agtaatgtta aaccattttt ttaattctaa atcaaatcac tttcacaaca 60  
 gtgaaaata gtgactgtt aagggtgcc actgtacata tcatttcattt ctgactgggg 120  
 tcaggactc gtccatgtcc acaagggttgg cggaggagg gtggaggccta agaacacaca 180  
 aaacacaaaa aagaaggaa agctgccttg cgacaggat gagggtgtt gcttgcgg 240  
 ggatgtggg aagggggcctc ctgttgggg ccggaggccatc aggtcccaat cagotctccat 300  
 15 gcctactta gtcctcgca gaggggtgatgg gggggccatc gaggttcaaa atcaatggc 360  
 atttggccag cttggcttta ctaacagggtt cccagagtgc ctctgttgc tgagcttc 420  
 tggctcaact cttatccatc gaagagtccaa atatgttcat ttccatccc acaaactttc 480  
 atttatccctt tggaaaccca ttctgttgc gtccatctga cttaaatgtt ctctccccc 540  
 20 actatgtggg ggcactgcac tgagggggtt cccaccaatc ttctttagat aagagacata 600  
 ccaggacggcc ctgcacattt cgggttttcc agaaagggtt aaaaagagca ctttttagt 660  
 ggtgcggcagg aatgtttaaa atctatcagg caactatcaa agctgtgtt ttcttcatt 720  
 caagtgttgc cggcatatc accacatc caatacttta ttatgttgc tttaaacac 780  
 tgaacttcgt tggtagacagg tacaaaaggag aagagatggg gactgttgaag agggggggc 840  
 ttccatccatc ttcttcataa tgatgtttttt cttaaatgttgc agactgttataa ttgaaaaaa 900  
 25 gcaatagatg ggggttctca cttatgttgc ttgttgcggc ggggttagcctt gggacgtgt 960  
 ggatgtggcaaa tgtagggaga gcccccaagg aaaaacccatc ttccctccatc ttgggtgtt 1020  
 ccagaagaagg gctggatgtt tgggtatgg ctttttttttccatc agggatgttgc 1080  
 aggtgttgcacatc ttcttccatc ttgttgcggc ctttttttttccatc agggatgttgc 1140  
 ttatgttgcact gaaaatccaa tcaatggat tggaaaggatc ttatcccccatttccatc 1200  
 30 gaggaaatggc cacacaaatc catgttgcgttggccatccatc ttcttccatc agccgttgc 1260  
 acaatccatc aggggttgc ttcttgcgttgc ttttttttttccatc agggatgttgc 1320  
 caaggatgttgc ttttttttttccatc ttatgttgc atccatcggc atccatcggc 1380  
 ccccttccatc ttcttcatttccatc ttatgttgc ttgttgcggc ctttttttttccatc 1440  
 35 gcatgttgc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 1500  
 attcaatgttgc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 1560  
 tcccaatccca accaaatggcc ttatgttgc ttgttgcggc ctttttttttccatc 1620  
 ctccgcgttccatc ttatgttgc ttgttgcggc ctttttttttccatc ttatgttgc 1680  
 40 agggagaaaatc ctgtatggaa acctgtgttgc taaggccatc ttatgttgc ttgttgcggc 1740  
 tggccggaaa ccaggaaatc ttatgttgc ttgttgcggc ctttttttttccatc 1800  
 ccaggacccatc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 1860  
 ctactgcgttgc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 1920  
 45 ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc ttatgttgc 1980  
 ctatgttgc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2040  
 tgaaaatattt ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2100  
 tgaaaatattt ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2160  
 50 tgaaaatattt ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2220  
 tgcaatggcc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2280  
 gctctgttgc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2340  
 ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc ttatgttgc 2400  
 ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc ttatgttgc 2460  
 55 gtcagagcc ttggccatggc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2520  
 catgttgcacc aaggccacaa attagaaagag gctgttgcggc aactgttgc 2580  
 ggggtgttgc  

<210> 48  
 <211> 1553  
 <212> DNA  
 <213> Human

<400> 48

60 tttttttttt tttttgtatt ctgggacaaat taagtttat ttttcatata tatatatat 60  
 ttcatatata tataatatacatatataaa gaaacaaattt tccaaatattt caccactgc 120  
 aaaatccatc atacacatcat atgttgcacat acacacacac agacacacaca accccaaatc 180  
 ctatgttgc ttttttttttccatc ttccatgttgc ctttttttttccatc ttatgttgc 240  
 65 gggggccatggc ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc 2460  
 ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc ttatgttgc 300  
 ttttttttttccatc ttatgttgc ttgttgcggc ctttttttttccatc ttatgttgc 360

ccatcaagag ggctatggga gccaagtcaa cacgggggat tgaggctaat tcacctaagc 420  
 tcgaaaacag cgcccaagttt ctcacccgcg gcacgcgtc tttttttttt ttttctcg 480  
 gacggagttt ctgtgttgc cccaggctgg agtgcgttg caccgtctcg gtcactgtca 540  
 agtcacactt tttttttttt tttttttttt ttttctcg 600  
 5 tagtgtccaa ccactacggc tagttaat ttttttttat tttagtaga gacagggtt 660  
 cacctgttta gccaggatgg tttttttttt ttttctcg cccggccgtt cggccctccca 720  
 aagtgttggg ttacacggcg tgacccacca caccctggcc cggcactgtat tttaaagg 780  
 atgacacccat ttctggctt ctgaccaaaag aaaaatgtc acaggagact ttgaagaggc 840  
 agacaggagg gtggtggccag caacactgcg gttttttttt tttttttttt ttttctcg 900  
 10 cggaggggtt gtggaaacggc cacttcaaca tggcaggcg cttttttttt ttttctcg 960  
 atttcgttgg tttttttttt ttttctcg actttttttt ttttctcg 1020  
 aggttaccca gttttttttt ttttctcg tttttttttt ttttctcg 1080  
 aaaaaacacg ttctgtcaaga aacttcttca cccggcttggg agacttggggc tttttttttt ttttctcg 1140  
 15 ggtttaggtt cttttttttt ttttctcg gggatgttgg tttttttttt ttttctcg 1200  
 gggccaaatg gggatgttgg tttttttttt ttttctcg tttttttttt ttttctcg 1260  
 cggggggggc agggatgttgg tttttttttt ttttctcg tttttttttt ttttctcg 1320  
 cggggggggc agggatgttgg tttttttttt ttttctcg tttttttttt ttttctcg 1380  
 tcagatcgat ttatttttttt cccttgcgtc ecggggccct tttttttttt ttttctcg 1440  
 20 gggggggggc catttttttt tttttttttt ttttctcg tttttttttt ttttctcg 1500  
 tacagacccg gggggtagctg gttttttttt ttttctcg tttttttttt ttttctcg 1560

<210> 49  
 <211> 921  
 <212> DNA  
 25 <213> Human  
 <400> 49

\*  
 30 ctgtggtccc agtacttcgg ggggggtt gttttttttt ttttctcg 60  
 tttttttttt ttttctcg 120  
 gtctccaaatg acaaaaacaa aaaaggcaga acgtgttgg gttttttttt ttttctcg 180  
 gttttttttt ttttctcg 240  
 tccggggggg tttttttttt ttttctcg 300  
 gaaggcccccc ggggggttggg gttttttttt ttttctcg 360  
 35 ggagggtggg gttttttttt ttttctcg 420  
 tggcgtctgttgg tttttttttt ttttctcg 480  
 tggcgtctgttgg tttttttttt ttttctcg 540  
 ccccttgcata tttttttttt ttttctcg 600  
 ccacgtgtttt tttttttttt ttttctcg 660  
 cttttttttt ttttctcg 720  
 40 tttttttttt ttttctcg 780  
 tttttttttt ttttctcg 840  
 tttttttttt ttttctcg 900  
 tcagatgtttt ggggggggg 960

45 <210> 50  
 <211> 338  
 <212> DNA  
 <213> Human  
 50 <400> 50

atgtatgtatc tagatgttcc accgtaaaat caaaacacaa aaccctactg actcatttttcc 60  
 55 tttttttttt ttttctcg 120  
 tttttttttt ttttctcg 180  
 catgtttctgtt tttttttttt ttttctcg 240  
 aacgacatgtt tttttttttt ttttctcg 300  
 gttttttttt ttttctcg 360

60 <210> 51  
 <211> 1191  
 <212> DNA  
 <213> Human  
 65 <400> 51

ctagcaaga ggttaaacagag ctttgtacaa acacacacag accaacadat cggggatgg 60  
 ctgtgttgc tttagcaggc ggtgttacaa acactcgatg tgggtgcct ctgtgcact 120  
 cctggaaaat aatgttgg gtaaggaaata gtaataaataaa aataatgtcc tgtaactgt 180  
 5 gacatataca acaaagagct ggcatctct gaaggaaaag ggcttgccg ctgtgcctc 240  
 aactgttgc gtcaaccat gccggaccc tcagcgctg tctccccccg acaccctat 300  
 tacatgttc tgctggctc gatctgtca tctgtcgaa gacgtctctg acaagtccgg 360  
 aattttctta ttttctcaact ggtgcaaaag gggtttctt ccttgcctt ctgtgtcac 420  
 10 ccccgctct ctccccccagg aggtctctt attttatgtt gttttgtat tgcttcccg 480  
 tctgtactgt ctgtactt aataatggaa aagctgtat ggtgaaggaa agactccgg 540  
 ccatacaca aaaaagaaaa atacaggaa aataatcaaa gaagctctg aaaataggg 600  
 15 aacaaacata aagacccat catttggaa aaaaaggccc gaggagaaaa tggcttca 660  
 atggaaatcg cagcggaaaa gaacaggaaag agatgttggaa gcaaaatcaa caacggcag 720  
 accaggatca ggtttttttt caaatgttcc tcaggcttgc aagaaatgtt caagatcttc 780  
 20 aaaaggcttca actgcataat tcaacggaa aagaggccat tttttttttt tttttttt 840  
 ttggccggc aacacaaatc attataatgt ctgtgtttttt gggatggaa gaaagggcag 900  
 aaggatcta ttggacatcc ttttttttcc ttttttttcc ttttttttcc ttttttttcc 960  
 cttaggttaag gaaggagata aatgttggaa aaaaatgttcc ttggaaatgtt acaggatctt 1020  
 tataatgtat gggaaataaa gttttttttt aatgttggaa aatgttggaa aatgttggaa 1080  
 ctttttttttt ctctggccat cagatgttcc tttttttttt ttttttttcc ttttttttcc 1140  
 atggccaaaaa gtccatgttca ttcaatgttcc ttggatgttcc aatgttggagg t  
  
 <210> 52  
 <211> 1200  
 <212> DNA  
 25 <213> Human  
  
 <400> 52  
  
 30 aacagggttcttccat caaaaaatccgg ctggggatccg gtgcgccttcc cctggctcc 60  
 tgcacccccc gctcccccgg ctcaacggaaat ttttttttttccat ctttttttttccat 120  
 actacaggca cacacccatca tccggccatcca attttttttttccat ttttttttttccat 180  
 cgttttttttccat ctttttttttccat ttttttttttccat ttttttttttccat 240  
 aataatataat atccatgttcc ttttttttttccat ttttttttttccat ttttttttttccat 300  
 accaaatccat atccatgttcc ttttttttttccat ttttttttttccat ttttttttttccat 360  
 ttggccggcc ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 420  
 ttctgtatgttcc ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 480  
 35 agggccgttcc attttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 540  
 atatgtatgttcc ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 600  
 ttcaaaaaaa ggttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 660  
 40 tgcttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 720  
 acctgttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 780  
 actctgttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 840  
 gatttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 900  
 45 gaataatccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 960  
 agatgtgggg ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 1020  
 gtcgttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 1080  
 ctatggccat gtttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 1140  
 ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 1200  
  
 50 <210> 53  
 <211> 989  
 <212> DNA  
 <213> Human  
  
 55 <400> 53  
  
 aaggccaccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 60  
 ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 120  
 60 gatccatataat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 180  
 agatgtactt ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 240  
 ggttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 300  
 cgactgttat gatgttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 360  
 gtttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 420  
 65 aggttcaatccat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 480  
 cccggatataat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 540  
 cccggatataat ttttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 600



<210>	56
<211>	1636
<212>	DNA
<213>	Human
<400>	56
10	cttgaatgaa gctgacacca agaaccccg gaagagcttg ggcccaaaggc aggaaaggga 60 agcgctcgag ttggaaaga accgtctgtg ctggccgac tcbaaggccc gcgcggccac 120 cagtttttgtt ggaattccgat ctgtggaaacc tgaggcgtcg cttcttccttccca agatggcttc 180 tggttttgtt ggttccaaagg acactgtcat gtccaaactgt tccccctggcc gttggaggg 240 cagtttatcc taaaagggtt tggaaaccaa accggcaaga gcaaaaaaggtaa gacggaaagg 300 cgggccggcc aaaaaggaaa gacgtctggc tttgtgtcaca ttgtctgggg gttggccctt 360 15 agccgtcgcc cttecccccc cagggcggaa ctctggccac gcccacccccc ccaatgtcccc 420 gatgttccctt gctctttgtt tgctacgggat ctcggatgtc ggcacatccaa gatcttgggg 480 gtgcagacac ggctctcgat tttgaatctt tccggccacc aaatgtctgt gagagatctg 540 agcttcacac ccaggatggc tttgtattttg gtctcccggtt caccggataaa gactcttcgc 600 atctggggca tttataaaca cggtaaaacag attcacgttgtt tttatccggccaa cttgtcgatgg 660 gttactgtt gttccatccccc cccagatgtc acgtatgttgc gttctggccgg tttggagaaq 720 tcggttttttt tttatggatcat ggggtttttttt acgtttttttt gggatgttca gggccatccaa 780 aggatgtttt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 840 gatataatgg tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 900 accagggtttt accccggccat gttatgttccat gttttttttt gttttttttt gttttttttt 960 ttgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1020 ttggccctttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1080 acatttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1140 ttggggccggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200 ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1260 acatcaacaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1320 acatcaacaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1380 ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1440 ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1500 35 aagacacattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1560 aagacacattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1620 gaccctgtgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 
40	<210> 57
<211>	460
<212>	DNA
<213>	Human
<400>	57
45	ccatgtgtt atgagagaga gagagattgg gaggggaggag gagctacta gcgcatatgt 60 gcctccagggtt ggctgtcgat gtgtgttgggg gtggacccatgg tggaaaggaaa gacaaaaaaa 120 tggaaatggc taaaggccggc gcctgggggtt ggaggcccgat cccattttttt tgacggccgg 180 ggcaggaggcc cagcaagggtt gcctccatcc cccaggatctt ggagggggctt gagacatcc 240 50 atcccccccgat agccctttttt caccatccat cctgtccacgc cctaaatgttgc cttttttttt 300 aactggggctt gggggatccat atgacgttgc acgtccggatgg ctggggacttgc aaccccaacca 360 gcctctttaga ccacgggtttt tttccatcat gggatgttgc agactccacgc cttttttttt 420 ccgagatctgat attcgtatccat atgggtatccat cttttttttt 
55	<210> 58
<211>	1049
<212>	DNA
<213>	Human
<400>	58
60	atctgtatcaa gaataacctac cttgttactt ctggggatgtt ttctgttccat tttttttttt 60 tgaggaccaa gatatactttt tttacagagg cactttttttt gtctaaacaca gacacccatccaa 120 tgaggaccaa gatatactttt tttacagagg cactttttttt gtctaaacaca gacacccatccaa 180 cagcagacact ttcccttgggg ggtttttttt cttttttttt cttttttttt cttttttttt 240 gtttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 300 65 qttatctttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360 qttatctttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 

15 <210> 59  
<211> 747  
<212> DNA  
<213> Human

```

<400> 59
20 tttttaaat cacatatggc ttctttgacc ccatcaaata acttttattca cacaacgctc 60
cctaatttaa caaaaggctca gtcattccata cacataggg gtccacagat gttcaaggaa 120
cttaataatata atgtatccata ccaaaacccaa taaaaaactt acaaaaaaaat ttccatataaa 180
gttgttccaca ctggatgtccct agatattacccg ctcttggtca aaaaaaggaa ataaaggaaa 240
atagattttat taacttagttt gggaaactta ttcttggtct ggcttaaaaac ctcccttcacg 300
ctgtctgtcc ccacacaaat gtttaaaggag tcactgcata gtactccccg gctctgtatca 360
aaaggacccc ctggccacaa agatggccat gggcccttggaa aggtccctt ccttcctgtgg 420
gcttcctttag aaacccacaa ggacggccctc ctgtgtata cccgttataaa ccttaggggg 480
ccctcgccga ggcaacggca gtggacttcat ctgggttccat gtgttagatc ctaaacatcg 540
30 ccaatattttt ggcacacacta ctggtttacc ttggaggca tttctccaga cagaacgccc 600
tttgaaggctt ggttggggcc gatcagatgg acacccgtgt ttgtctcgaa gggctccaca 660
gccccatggcc acatgtttttt gatggatggta tctcttgact tctgtttccca gtcgacccggc 720
ccccatattttt atgtatccata ccccccgc

```